PI
AVIR icon

PineBridge Investments’s Atea Pharmaceuticals AVIR Stock Holding History

PineBridge Investments’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,336
Closed -$115K – 561
2023
Q3 		$115K Buy
+38,336
New +$130K ﹤0.01% 631

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PineBridge Investments's AVIR Position: Q4 2023 in Review

PineBridge Investments sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 38,336 shares — an estimated $115K sold.

PineBridge Investments first reported a position in AVIR in Q3 2023 and held it in 1 quarter. The position peaked at $115K in Q3 2023. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • PineBridge Investments reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • PineBridge Investments sold 38,336 Atea Pharmaceuticals shares in Q4 2023, an estimated $115K.
  • PineBridge Investments first reported a position in Atea Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • PineBridge Investments's Atea Pharmaceuticals position peaked at $115K in Q3 2023.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on PineBridge Investments's 13F filing for Q4 2023, filed 13 Feb 2024.